Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
18 Apr 24
8-K
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
8 Apr 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
21 Mar 24
8-K
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
12 Mar 24
8-K
Kineta Announces Restructuring and Exploration of Strategic Alternatives
29 Feb 24
8-K
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
17 Jan 24
8-K
Regulation FD Disclosure
5 Jan 24
8-K
Entry into a Material Definitive Agreement
15 Dec 23
EFFECT
Notice of effectiveness
15 Nov 23
424B3
Prospectus supplement
13 Nov 23
CORRESP
Correspondence with SEC
9 Nov 23
UPLOAD
Letter from SEC
9 Nov 23
8-K
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
6 Nov 23
S-3
Shelf registration
3 Nov 23
10-Q
2023 Q3
Quarterly report
3 Nov 23
8-K
Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update
3 Nov 23
8-K
Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
3 Nov 23
D
$2.89 mm in options / securities to be acquired, 1 investor
20 Oct 23
8-K
Entry into a Material Definitive Agreement
17 Oct 23
8-K
Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
5 Oct 23
424B5
Prospectus supplement for primary offering
5 Oct 23
8-K
Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy
4 Oct 23
8-K
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
3 Oct 23
8-K
Kineta to Participate in Upcoming Investor Conferences
31 Aug 23
8-K
Other Events
16 Aug 23
8-K
Regulation FD Disclosure
11 Aug 23
10-Q
2023 Q2
Quarterly report
11 Aug 23
8-K
Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update
11 Aug 23
8-K
Entry into a Material Definitive Agreement
21 Jul 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
3 Jul 23
8-K
Kineta to Receive $5 Million Milestone Payment from Merck
29 Jun 23
8-K
Departure of Directors or Certain Officers
28 Jun 23
EFFECT
Notice of effectiveness
13 Jun 23
424B3
Prospectus supplement
12 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
9 Jun 23
CORRESP
Correspondence with SEC
8 Jun 23
UPLOAD
Letter from SEC
7 Jun 23
8-K/A
Financial Statements and Exhibits
2 Jun 23
S-3
Shelf registration
1 Jun 23
Latest ownership filings
4
Shawn Iadonato
16 Apr 24
4
CRAIG W. PHILIPS
16 Apr 24
4
Keith Baker
16 Apr 24
4
Thierry Guillaudeux
16 Apr 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13D/A
Iadonato Shawn
12 Feb 24
SC 13G/A
Magness Charles
12 Feb 24
4
Raymond J. Bartoszek
6 Dec 23
4
CRAIG W. PHILIPS
30 Nov 23
4
Shawn Iadonato
30 Nov 23
4
Marion R Foote
12 Oct 23
4
CRAIG W. PHILIPS
21 Sep 23
4
Pauline Kenny
21 Sep 23
4
Shawn Iadonato
21 Sep 23
4
Raymond J. Bartoszek
21 Sep 23
4
Keith Baker
19 Sep 23
4
Raymond J. Bartoszek
19 Sep 23
4
Thierry Guillaudeux
15 Sep 23
4
Scott J. Dylla
5 Jul 23
4
Kimberlee C Drapkin
5 Jul 23
3
Scott J. Dylla
5 Jul 23
3
Kimberlee C Drapkin
5 Jul 23
4
CRAIG W. PHILIPS
16 Jun 23
4
Pauline Kenny
16 Jun 23
4
Shawn Iadonato
16 Jun 23
4
Raymond J. Bartoszek
16 Jun 23
4
Keith Baker
16 Jun 23
4
CRAIG W. PHILIPS
14 Apr 23
4
Richard Peters
14 Apr 23
4
Pauline Kenny
14 Apr 23
4
Shawn Iadonato
14 Apr 23
4
Thierry Guillaudeux
14 Apr 23
4
Marion R Foote
14 Apr 23
4
Raymond J. Bartoszek
14 Apr 23
4
Keith Baker
14 Apr 23
4
David Arkowitz
14 Apr 23
4
CRAIG W. PHILIPS
21 Mar 23
4
Pauline Kenny
21 Mar 23
4
Shawn Iadonato
21 Mar 23
SC 13G
Magness Charles
14 Feb 23